Intercept pharmaceuticals inc.

Contact Us For more information call: (844) 782–4278 Corporate Headquarters 305 Madison AvenueMorristown, NJ 07960 T: (646) 747–1000 San Diego Office 3636 Nobel Drive, Suite 475,San Diego, CA 92122 T: 858-652-6800Apr 13, 2023 · MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financial results on Thursday, April 27, 2023, and provide an update on the commercial launch strategy for ... By: Alfasigma S.p.A. via Business Wire. November 08, 2023 at 09:12 AM EST. Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of …About us We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver...

Nov 8, 2023 · Following the completion of Alfasigma’s successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash ... Director. Keith Gottesdiener, M.D. has served as a member of our Board of Directors since July 2016. Since July 2020, Dr. Gottesdiener has served as the President and Chief Executive Officer and as a director of Prime Medicine, Inc., a biopharmaceutical company based in Cambridge, Massachusetts. Prior to that, from October 2011 until March 2020 ...

Intercept Pharmaceuticals Inc.: Intercept is a biopharmaceutical company that manufactures drugs to treat non-viral liver disease. BioNTech SE: ...

Intercept Pharmaceuticals, Inc.ICPT announced a restructuring program in the wake of the recent complete response letter (CRL) issued by the FDA to its new drug application (NDA) seeking approval ...Intercept Pharmaceuticals, Inc. November 8, 2023 at 9:13 AM · 11 min read. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept ...Our Pipeline. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases, with a focus on those with high unmet need. We are leveraging our decades of research and background in bile acids and FXR agonism to expand our pipeline to deliver effective treatments for the growing ...Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021-01-13. EX-99.1.Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in …

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ...

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended on December 31, 2021.

MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at …Intercept Pharmaceuticals Inc: Overview. Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments …Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases.BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. ("Alfasigma") and Intercept Pharmaceuticals, Inc. ("Intercept") announced today the completion of the ...Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases ...Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH ...

The most common side effects of OCALIVA include: tiredness; stomach pain and discomfort; rash; joint pain; mouth and throat pain; dizziness; constipation; swelling in your hands, ankles, or feet; fast or irregular heartbeat; fever; changes in how your thyroid gland works; dryness, irritation, redness, crusting or drainage of the skin (eczema).Agreement and Plan of Merger, dated September 26, 2023, among Intercept Pharmaceuticals, Inc., Alfasigma S.p.A. and Interstellar Acquisition Inc.* 99.1 Press Release of Intercept Pharmaceuticals, Inc., dated September 26, 2023 104 Cover Page Interactive Data File (embedded as Inline XBRL document)Follow. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...MORRISTOWN, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced positive topline results from a new interim analysis of its ongoing pivotal Phase 3 ...Jun 22, 2023 · Intercept Pharmaceuticals, Inc. June 22, 2023 at 5:45 PM · 3 min read Company to discontinue all NASH-related investment and restructure the Company’s operations to strengthen its focus on rare ...

Jan 7, 2022 · 01.07.22. LONDON, [July 01], 2022 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, today announced that it has successfully completed the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada, and all other markets ...

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Intercept stockholders who need additional copies of the Offer to Purchase, Letter of Transmittal or related materials or who have questions regarding the tender offer should contact the ...MORRISTOWN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the …For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, please contact: Jeffrey P. Campisi ...Jan 19, 2023 · MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... As pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...

MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...

Learn more about ongoing Intercept-sponsored clinical trials below. Primary biliary cholangitis (PBC) Intercept has two ongoing Phase 2 studies, 747-213 and 747-214, that are designed to explore a range of therapeutic doses for the combination of OCA and bezafibrate. Study 747-213 is for patients outside of the United States. Study 747-214 is for patients … Continued

Mar 2, 2023 · Selected Fourth Quarter and Full Year 2022 Financial Results. Intercept recognized $77.2 million in U.S. net sales in the fourth quarter 2022 as compared to $68.7 million in U.S. net sales in the ... THIS INDENTURE, dated as of August 17, 2021 between Intercept Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), and U.S. Bank National Association, a national banking association organized and existing under the laws of the United States (the “Trustee”), WITNESSETH: WHEREAS, the Issuer may from time to time duly authorize …NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...For more information about Intercept, please contact: Lisa DeFrancesco +1-646-565-4833 [email protected] Christopher Frates +1-646-757-2371 [email protected]. Source: Intercept Pharmaceuticals, Inc.৩০ মার্চ, ২০১১ ... (DSP) and Intercept Pharmaceuticals, Inc. (Intercept) today announced that they have entered into an exclusive licensing agreement for the ...40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitisAdditional Phase 2 trial of the OCA-bezafibrate combination remains ongoing in Europe. MORRISTOWN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral …Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On September 26, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alfasigma S.p.A. (“Alfasigma”) and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (“Purchaser”).Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced its financial results for the quarter ended on June 30, 2023.For more information about Intercept, please contact: Lisa DeFrancesco +1-646-565-4833 [email protected] Christopher Frates +1-646-757-2371 [email protected]. Source: Intercept Pharmaceuticals, Inc.

Jun 3, 2022 · MORRISTOWN, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced results from two studies designed to evaluate clinical outcomes in patients with PBC on Ocaliva ... Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that top-line data from its Phase 3 REVERSE trial ...Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced its financial results for the quarter ended on June 30, 2023.Instagram:https://instagram. soundhound stock newscan i make money forex tradingstock day trading softwarefinancial planner pittsburgh Intercept Pharmaceuticals, Inc. ICPT announced that the FDA has accepted the company’s new drug application (NDA) for obeticholic acid (OCA) that seeks accelerated approval for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH). The FDA indicated that it considers this a complete Class 2 ...May 26, 2021 · NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has ... liberty gold stockcapital city bank group Intercept Pharmaceuticals, Inc.ICPT announced that the FDA has accepted the company’s new drug application (NDA) for obeticholic acid (OCA) that seeks accelerated approval for the treatment of ... best investing newsletter NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the …The company inked the buyout after two FDA rejections for Ocaliva in NASH-related liver fibrosis and a recent attempt at cutting costs.